Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Grueger

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|January 10, 2025
Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic WorldJens Grueger, Vaidyanathan Srikant
Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2021
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspectiveGiovanni Tafuri, Andrea Bracco, Jens Grueger
Expert Review of Pharmacoeconomics & Outcomes Research|March 13, 2025
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 updateGiovanni Tafuri, Andrea Bracco, Jens Grueger
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 3, 2025
Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From EuropeJens Grueger, Kristi Martin, Sean D Sullivan
American Journal of Clinical Dermatology|April 12, 2006
Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of ageCharles N Ellis, Kristijan H Kahler, Jens Grueger, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 13, 2021
Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review ReportsLisa M Bloudek, Victor Nguyen, Jens Grueger, et al.
Journal of Managed Care & Specialty Pharmacy|May 7, 2025
The consequences of pharmaceutical tariffs in the United StatesSean D Sullivan, Jens Grueger, Aidan P Sullivan, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|May 18, 2011
Proceedings from a symposium of the Canadian Association of Population Therapeutics--2010 annual conferenceScott Gavura, Angela Rocchi, Mona Sabharwal, et al.
Health and Quality of Life Outcomes|July 31, 2007
Quality of life in infants and children with atopic dermatitis: addressing issues of differential item functioning across countries in multinational clinical trialsStephen P McKenna, Lynda C Doward, David M Meads, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 25, 2024
Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019Louis P Garrison, Boshen Jiao, Zizi Elsisi, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|January 10, 2025
Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic WorldJens Grueger, Vaidyanathan Srikant
Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2021
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspectiveGiovanni Tafuri, Andrea Bracco, Jens Grueger
Expert Review of Pharmacoeconomics & Outcomes Research|March 13, 2025
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 updateGiovanni Tafuri, Andrea Bracco, Jens Grueger
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 3, 2025
Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From EuropeJens Grueger, Kristi Martin, Sean D Sullivan
American Journal of Clinical Dermatology|April 12, 2006
Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of ageCharles N Ellis, Kristijan H Kahler, Jens Grueger, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 13, 2021
Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review ReportsLisa M Bloudek, Victor Nguyen, Jens Grueger, et al.
Journal of Managed Care & Specialty Pharmacy|May 7, 2025
The consequences of pharmaceutical tariffs in the United StatesSean D Sullivan, Jens Grueger, Aidan P Sullivan, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|May 18, 2011
Proceedings from a symposium of the Canadian Association of Population Therapeutics--2010 annual conferenceScott Gavura, Angela Rocchi, Mona Sabharwal, et al.
Health and Quality of Life Outcomes|July 31, 2007
Quality of life in infants and children with atopic dermatitis: addressing issues of differential item functioning across countries in multinational clinical trialsStephen P McKenna, Lynda C Doward, David M Meads, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 25, 2024
Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019Louis P Garrison, Boshen Jiao, Zizi Elsisi, et al.
Pageof 2